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Abstract
Backgrounds and Aims: When hepatocyte proliferation is impaired, liver regeneration proceeds from the division of non
parenchymal hepatocyte progenitors. Oval cells and Small Hepatocyte-like Progenitor Cells (SHPCs) represent the two most
studied examples of such epithelial cells with putative stem cell capacity. In the present study we wished to compare the
origin of SHPCs proliferating after retrorsine administration to the one of oval cells observed after 2-Acetyl-Amino fluorene
(2-AAF) treatment.
Methodology/Principal Findings: We used retroviral-mediated nlslacZ genetic labeling of dividing cells to study the fate of
cells in the liver. Labeling was performed either in adult rats before treatment or in newborn animals. Labeled cells were
identified and characterised by immunohistochemistry. In adult-labeled animals, labeling was restricted to mature
hepatocytes. Retrorsine treatment did not modify the overall number of labeled cells in the liver whereas after 2-AAF
administration unlabeled oval cells were recorded and the total number of labeled cells decreased significantly. When
labeling was performed in newborn rats, results after retrorsine administration were identical to those obtained in adult-
labeled rats. In contrast, in the 2-AAF regimen numerous labeled oval cells were present and were able to generate new
labeled hepatocytes. Furthermore, we also observed labeled biliary tracts in 2-AAF treated rats.
Conclusions: Our results srongly suggest that SHPCs are derived from hepatocytes and we confirm that SHPCs and oval
cells do not share the same origin. We also show that hepatic progenitors are labeled in newborn rats suggesting future
directions for in vivo lineage studies.
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Introduction
Hepatic regeneration after liver injury is normally accounted
for by division of mature hepatocytes. However, when hepato-
cyte division is impaired, proliferation of non parenchymal cells
occurs to eventually replace the injured parenchyma. A large
variety of animal models have been used to study the origin and
the role of these non-parenchymal liver stem cells and one
constant finding from these studies was the wide heterogeneity of
the stem cell populations involved. Two main categories of
putative hepatic progenitors have been described which differ
morphologically and phenotypically: oval cells (according to the
oval shape of their nucleus) and SHPCs (for Small Hepatocyte-
like Progenitor Cells)[1]. Other populations of putative stemcells
have been described but their actual existence is dubious, mostly
because the search for specific markers of hepatic progenitor cells
has not yet been completely successful. Indeed, most of the
initially described markers of oval cells are actually expressed by
biliary cells, fetal hepatocytes or even SHPCs. More recently-
described markers also pointed out to the mixed epithelial/
mesenchymal phenotype of oval cells [2]. The search for specific
markers is a critical issue since most of the knowledge regarding
t h eo r i g i na n dt h ef a t eo fl i v e rs t e mc e l l si sb a s e do ns u c h
phenotypic characterisation with the assumption that cells
expressing the same markers pattern may have a common
origin. As an example, a number of hematopoietic markers were
described in various models of oval cell proliferation (including
thy-1, CD34, Sca1) supporting the hypothesis that oval cells
might derived from bone marrow [3,4]. On the opposite, recent
studies revealed that hematopoietic markers may be not
expressed in the true stem cell fraction of the oval cell population
[5,6] thus indicating that oval cells are not from bone marrow
origin but may originate either from the canal of Hering as
suspected long ago [7,8] or from other hepatic stem cell niches
identified inside the liver [9]. The origin of SHPCs is also
controversial. Many previous lineage studies in the dipin as well
as in the retrorsine model of hepatic injury support the notion
that SHPCs derive from hepatocytes that escape the effect of
toxic compound [10,11,12]. However, it has also been suggested
that SHPCs originate from a new stem cell population or even
from oval cells [13,14]. However the latter hypothesis was refuted
by subsequent studies [15,16].
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7267In the present study, we wished to use in vivo genetic labeling to
trace the fate of specific cell populations in the liver after liver
intoxication with two different compounds: retrorsine which is
known to induce proliferation of SHPCs and 2-Acetyl amino-
fluoren (2-AAF) which results in the proliferation of oval cells. In
adult animals, mature hepatocytes were specifically labeled and
their lineage was analyzed in response to either drugs. We also
labeled cells with lacZ recombinant retroviral vectors injected at 2
days of age in newborn animals that were subsequently treated
with either of the two drugs.
Results
In a first set of experiments we analysed the fate of hepatocyte in
the retrorsine and 2-AAF models of liver injury after genetic
labeling of hepatocytes in adult animals. Hepatocytes were labeled
with recombinant Moloney Murine Leukemia Virus (MoMuLV)
vectors carrying the nls lacZ gene after a short treatment with
cyproterone acetate (CPA) and triiodothyronin (T3) as previously
described [12,17]. This protocol will force hepatocytes in the cell
cycle to render them infectable with MoMULV vectors [18]. To
circumvent any cytotoxic immune response to b-galactosidase and
allow long term transgene expression, animals received a single
dose of a recombinant adenoviral vector carrying a modified
CTLA4Ig as previously described. This treatment is known to
suppress immune response against b–galactosidase for at least 18
weeks in most of the animals with no alteration of liver physiology
[19].
After labeling, animals were divided in two cohorts and received
retrorsine (n=10) or 2-AAF (n=9) according to the schedule
depicted in Figure 1. Liver specimens were harvested at the time of
hepatectomy as well as at sacrifice in all animals.
In the retrorsine group, the liver lobes removed at partial
hepatectomy revealed a mean proportion of 6.363% of b-
galactosidase positive hepatocytes (Table 1). This value is in the
same range than in animals that did not receive retrorsine [11,12].
We also observed, that cells other than hepatocytes were not
labeled (,0.01%) as previously described [12]. The labeled cells
were randomly distributed in the liver lobule, indicating
indiscriminate infection of hepatocytes with the retroviral vector
[11,20,21]. In two animals (R4 and R6 in Table 1), no b-
galactosidase positive hepatocytes were found. However, anti b-
galactosidase antibodies were found in the serum indicating that
some animals may escape immune suppression induced by
CTLA4Ig. Four animals were sacrificed at day 15 after
hepatectomy. In these animals the mean proportion of b-
galactosidase positive hepatocytes was 4.761.5% (Figure 2).
Moreover, we observed the presence of clusters of small-size
hepatocytes (less than 20 cells in size) which corresponded to Small
Hepatic Progenitor cells (SHPCs) as previously described [10].
These clusters were highly labeled with anti Ki67 antibody
indicating a high proliferation index. As shown in Figure 3A some
clusters also expressed b-galactosidase and the proportion of
clusters expressing b-galactosidase was similar to the proportion of
hepatocytes that were initially labeled (Table 1). Four animals
were sacrificed at 4 weeks after hepatectomy. In these animals, we
found larger clusters of small hepatocytes, resulting from the
division of SHPCs as expected in the retrorsine model at this time
point [10,11]. Moreover, at that time the Ki67 labeling was much
lower, indicating a drop in cell proliferation in the clusters. We
Figure 1. Schematic diagrams of retrorsine and 2-AAF treatments.
doi:10.1371/journal.pone.0007267.g001
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(Figure 3B). Because these large clusters frequently merged,
precise quantification of the proportion of b-glactosidse positive
clusters was not possible. However, the mean overall proportion of
b–gal positive hepatocytes was 4.660.7%. We never detected
clear oval cell proliferation in any section at sacrifice although
transient ductular reaction was sometimes seen. Cytokeratin
staining was limited to biliary epithelial cells. These data
recapitulated our previous results and showed that the mean
proportion of b-galactosidase positive hepatocytes was not
statistically different in livers harvested at hepatectomy or at the
two times of sacrifice (p=0.4 using ANOVA). Moreover, the
proportion of b-galactosidase clusters at day 15 was identical to the
proportion of labeled hepatocytes, strongly suggesting that the
clusters originated from the labeled hepatocytes that were present
in the liver before retrorsine administration. To confirm that the
presence of merging clusters of various sizes did not impact the
counting of hepatocytes, we verified that b-galactosidase enzy-
matic activity was identical in liver homogenates from rats
sacrificed at day 15 or day 30 (17.966.1 ng bgal/mg protein at
day 15 vs 18.565.6 at day 30; p=0.9 using Student’s t test).
In the 2-AAF cohort (n=9), the mean proportion of b-
galactosidase positive cells at the time of hepatectomy was
4.561.36% (Figure 2) similar to the one observed in the retrorsine
group at hepatectomy (p=0.23 using Student’s t test). One animal
died immediately after hepatectomy from unknown cause. In the
liver of rats sacrificed at day 9 post hepatectomy (n=4)
immunohistochemistry revealed 0.960.25% of b-galactosidase
positive hepatocytes. Oval cells were detected in large amounts
and were positive for Gamma Glutamyl Transpeptide (GGT) and
b-catenin. They were also labeled with a panel of anti cytokeratins
antibodies which do not label hepatocytes but are known to detect
oval cells with a sensitivity and specificity greater that 99%
(Figure 3C–E) [22]. We never detected the presence of oval cells
that were positive for b-galactosidase. Four animals were sacrificed
one month after partial hepatectomy. In these animals the overall
proportion of b-galactosidase hepatocytes was 160.23%. Oval
cells were still present at that time, although in lower amounts, but
they were consistently negative for b-galactosidase expression. It is
noteworthy that in this cohort, we observed a significant decrease
in the number of b-galactosidase positive hepatocytes between
hepatectomy and sacrifice (p=0.01 using ANOVA). Lower
enzyme activity was also recorded at sacrifice (6.962.6 ng b-
galactosidase/mg prot at day 9 vs 7.4561.9 at day 30) (p=0.7
using Student’s t test). We also observed in the liver of animals at
sacrifice the presence of rare clusters of mature hepatocytes (from
2 to 10 clones/cm
2). These clusters were always larger than 20
cells (17% from 20 to 50 cells; 59% from 50 to 100 cells and 24%
more than 100 cells) (Figure 3F). We already observed such b-
galactosidase positive clusters after 2-AAF treatment and we
hypothesized that they originated from the division of hepatocytes
resistant to the toxic effect of 2-AAF [23]. We cannot completely
exclude that some of them arise from labeling of rare progenitor
cells because the proportion of these clusters was very low (less
than 1 for 2000 cells).
Overall, our data clearly established that after retrorsine
treatment the proportion of labeled hepatocytes was stable with
the presence of numerous small clones of labeled hepatocytes. In
contrast, following 2-AAF treatment the proportion of labeled cells
dropped and only rare large clusters of labeled hepatocytes were
detected. This indicated that liver regeneration proceeds from
different populations in retrorsin treated and 2-AAF treated adult
animals. After AAF intoxication, regeneration is known to proceed
from the division of oval cells that proliferate and gradually
differentiate into hepatocytes [1,24,25]. Thus in our model,
genetically-labeled hepatocytes were diluted by the proliferation of
non-labeled oval cells that proliferated and differentiated in non-
labeled hepatocytes.
In a second set of experiments we genetically labeled liver cells
by administration of recombinant nls LacZ MoMuLV vectors to
newborn rats. The proportion of labeled cells was highly variable
Table 1. Quantification of b-galactosidase positive
hepatocytes and clones in the liver of adult-labeled rats
treated with retrorsine.
%bgal
hepatocytes
%bgal
hepatocytes
%bgal
hepatocytes
% bgal
clones
rat number hepatectomy day 15 day 30 day 15
R1 11 7 10.1
R2 10.1 4.3 3.2
R3 7.2 4 5.7
R4 0
R5 4.3 3.6 4.6
R6 0
R7 6 4
R8 4.5 5.6
R9 4.4 4.6
R10 2.6 4.1
mean 6.3634 . 7 61.5 4.660.7 5.962.9
doi:10.1371/journal.pone.0007267.t001
Figure 2. Quantification of the number of b-galactosidase
positive hepatocytes in the liver of rat labeled at adulthood
and treated with Retrorsine (upper panel) or 2-AAF (lower
panel).
doi:10.1371/journal.pone.0007267.g002
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different time points.In these animals, we observed the presence of
a small proportion of non-hepatocyte cells that were labeled.
These cells were mainly in the portal tract represented 0.60% of all
labeled cells at day 15, 1.98% at 4 weeks and 1.3% at 7 weeks.
After labeling, animals were divided in two groups and received
either retrorsine or 2-AAF at six weeks of age (Figure 1).
In the retrorsine group (n=7) the proportion of b-galactosidase
positive hepatocytes was evaluated in the liver lobes removed at
partial hepatectomy. The mean proportion of b-galactosidase
hepatocytes was 1.5761% (Table 2). In the labeled cells
population, 1.83% of the cells were neither hepatocytes nor oval
cellsThe presence of b-galactosidase positive cells and the enzyme
activity were analysed at sacrifice in the same animals. We
observed a robust so-called ‘‘SHPC response’’ with the presence of
numerous clusters of proliferating hepatocytes, either isolated or
merging in large patches, some of which were also positive for b-
galactosidase (Figure 4A–B). As shown in Table 2 there were
slightly more b-galactosidase positive hepatocytes at sacrifice
(2.0761.4%) than at the time of hepatectomy. However this
difference was not statistically significant (p=0.79 by Student’s t
test) At the time of sacrifice it was not possible to quantify the
proportion of non-hepatocyte labeled cells. It is noteworthy that
we never detected oval cells in any section either by morphological
examination or by immunohistological staining (Figure 4C). This
confirm that SHPCs do not arise from oval cells. Although we
never detected a clear proliferation of other non parenchymal
cells, we cannot exclude in this setting that some labeled
hepatocytes derived from labeled progenitors.
In the 2-AAF cohort (n=4), the proportion of b-galactosidase
positive hepatocytes was also highly variable at hepatectomy.
However, in sharp contrast to the 2-AAF treated adult cohort,
there was no decrease in the proportion of b-galactosidase
hepatocytes between hepatectomy and sacrifice (p=0.63 using
Figure 3. Histological analysis of retrorsin and 2-AAF treated rat liver after genetic labeling of mature hepatocytes in adult animals.
Retrorsin model. (A) b-galactosidase positive cells gathered in clusters of small hepatocyte day 15. (B) same clusters at day 30 post hepatectomy. 2-
AAF model. Immunohistochemical detection of CKs (C), GGT (D), and b-catenin (E) expressed by oval cells. (F) Clusters of b-galactosidase positive
hepatocyte observed in the 2-AAF model. All sections are hematoxylin counterstained. All magnifications: 6400 except 6200 B and F.
doi:10.1371/journal.pone.0007267.g003
Table 2. % b-galactosidase positive hepatocytes in the liver
of rats labeled at birth.
treatment hepatectomy sacrifice ratio sacr/hep
retrorsine 0.5 1 2
retrorsine 0.5 0.7 1.4
retrorsine 1.4 2.2 1.57
retrorsine 1.7 1.4 0.82
retrorsine 3.4 4.4 1.29
retrorsine 2.2 3.6 1.63
retrorsine 1.3 1.2 0.92
mean 1.5761 2.0761.4 1.3660.41
2-AAF 5.2 8.6 1.65
2-AAF 0.4 0.6 1.5
2-AAF 4 4.9 1.23
2-AAF 0.2 0.5 2.5
mean 2.4762.5 3.6564.64 1.7260.54
doi:10.1371/journal.pone.0007267.t002
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galactosidase positive oval cells. (Figure 5A). b-galactosidase
expression in oval cells was confirmed by b-galactosidase and
CKs immuno colocalization coupled with confocal microscopy
(Fig. 5 B1–B2). The b-galactosidase positive oval cells were mainly
located around the portal tract, in the vicinity of the Hering canal,
suggesting that they may arise from transitional cells. The absence
of decrease in the number of b-galactosidase hepatocytes in these
animals in which a proliferation of labeled oval cells occurred,
strongly suggested a lineage relationship between the two
populations with labeled oval cells giving rise to labeled
hepatocytes. Along the same line, b-galactosidase positive
hepatocytes were frequently adjacent to oval cells even at day 9
after hepatectomy (Figure 5A) suggesting that oval cell differen-
tiation in hepatocytes is a rapid process. Another salient
observation was the presence of b-galactosidase positive cells in
Figure4.Histologicalanalysisoftheretrorsinmodelaftergeneticlabelingoflivercellsinnewbornrats.Retrorsin model. (A) Cluster of SHPCs
positive for b-galactosidase. (B) Hematoxylin and eosin staining showing large number of merging clusters 30 days post hepatectomy. (C)
Immunohistochemical detection ofCKs day 30 post hepatectomy.Oval cells are not detected. Hematoxylin counterstain. Magnification:6200 A–B:6400 C.
doi:10.1371/journal.pone.0007267.g004
Figure 5. Histological analysis of 2-AAF model after genetic labeling of liver cells in newborn rats. (A) Detection of b-galactosidase
positives oval cells. (B1) Immunofluorescent staining of CK in oval cells appearing in red (B2) colocalisation of CK with b-galactosidase appearing in
green. (C) Detection of b-galactosidase positive cells in the biliary cell population (arrows). (D) Detection of a positive cells (arrow) near the Hering
canal. Hematoxylin counterstain for A, C, D, Magnification: 6400 except for B: 61000.
doi:10.1371/journal.pone.0007267.g005
Lineage Analysis in Rat Liver
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were not frequent and present in 2% of the portal space analysed.
The presence of b-galactosidase positive oval cells and biliary
cells prompted us to analyse liver sections in a cohort of newborn
injected animals (n=5) sacrificed at 4 weeks of age (i.e. before any
treatment) to look for the presence of putative oval cell precursors.
In each animal, 37 to 75 portal spaces were carefully examined.
The mean proportion of portal space in which a single positive cell
was observed was 1266.5%. In these portal spaces, the positive
cells were most often in zone 1 and 3 of the portal space according
to the classification of Petersen and Shupe (Figure 5D) [26]. Only
two cells in zone 2 were observed indicating that biliary cells were
almost never observed.
Discussion
Genetic labeling with integrative gene transfer vectors is a
powerful approach to study cell lineage in various organs. In the
liver, the opportunity to label cells in vivo makes lineage study
feasible in the absence of any ex vivo manipulation of the cells that
will be studied. In the present study, we wished to use genetic
labeling with the nlsLacZ gene to compare the fate of mature
hepatocytes in two models of liver injury in which replication of
hepatocytes is impaired.
First we present evidence for the different cellular origin of
SHPCs and oval cells. SHPCs share antigenic characteristics with
hepatocytes and fetal hepatoblasts [14] but their origin has long
been debated. They may arise from a distinct population of stem
cells present in the liver [14,27]. Alternatively, it has been
suggested that SHPCs are derived from oval cells [13]. However
these results were not confirmed [15,16]. We previously presented
evidence that SHPCs are derived from mature hepatocytes
[11,12]. This hypothesis was also previously proposed in dipin-
induced toxic injury in mice and hepatocytes resistant to dipin
were shown to contribute to the regeneration process [10]. Our
present results show that when only hepatocytes are labeled in the
adult animals, the number of SHPC clusters expressing the label is
identical to the number of labeled hepatocytes before treatement.
Moreover, there is no variation in the overall proportion of b-
galactosidase hepatocytes after retrorsine administration. These
findings strengthen the hypothesis that ‘‘SHPCs’’ are the progeny
of hepatocytes as we previouslly suggested [11]. In contrast, after
2-AAF administration in adult labeled animals the number of
labeled cells drops significantly. This confirms that oval cells do
not arise from hepatocytes and do not share a common origin with
SHPCs. Although we cannot formally exclude the possibility that
putative stem cells are labeled and give rise to SHPCs, this seems
unlikely when labeling is performed in adult rats because: i) when
labeling is performed in the adult rat, hepatocytes account for
more than 99.9% of labeled cells using our protocol, ii) if non
hepatocytes progenitors would be activated after administration of
retrorsine, they should not be labeled by MoMULV vectors
injected long before retrorsine administration.
Second, we observed a clear difference between animals labeled
at adulthood or after birth. In newborn-labeled animals a
significant proportion of non parenchymal cells was labeled. This
precluded to draw any conclusion regarding the origin of mature
hepatocytes in the retrorsine modelAfter 2-AAF injury many oval
cells were labeled. In these animals the proportion of b-
galactosidase positive hepatocytes was stable in contrast to the
results obtained in adult-labeled animals indicating that oval cells
were able to generate hepatocytesin this setting. To our knowledge
this represents the first report of in vivo genetic labeling of oval
cells. Numerous studies have already demonstrated that oval cells
isolated from a donor liver and enriched with various systems can
give rise to hepatocytes after transplantation. Direct in vivo studies
of the fate of oval cells have been previously carried out using
3H-
thymidine as a marker more that 20 years ago. Tatematsu et al.
failed to get evidence for the conversion of oval cells to hepatocytes
after
3H-thymidine labeling of oval cells [28]. In contrast, Evarts et
al. observed transfer of radio-labeled thymidine from oval cells to
hepatocytes and suggested a precursor-product relationship
between oval cells and hepatocytes [25,29]. It is worth noting
that in this study differentiation of oval cells was rapid and 91% of
basophilic hepatocytes contained the label 9 days after partial
hepatectomy. Very low labeling was observed in acidophilic
hepatocytes that are hepatocytes not originating from oval cells. In
the present study we observed numerous labeled hepatocytes in
the vicinity of areas of b-galactosidase positive oval cells as early as
9 days after partial hepatectomy. b-galactosidase positive hepato-
cytes were intermingled with clusters of b-galactosidase positive
oval cells a situation compatible with a lineage relationship.
Because labeling occurred six weeks before 2-AAF administra-
tion, oval cells were not directly infected with MoMULV vectors.
Therefore it is likely that in the newborn, viral vectors were able to
infect hepatocytes as well as other precursor cells that were still
dividing at the time of infection. These labeled precursors were
thereafter detected in the portal spaces of the animals and may
include Hering cells. When 2-AAF was given to these animals, the
labeled precursors may have been activated to proliferate and give
rise to labeled oval cells. We cannot exclude that some other
precursor cells different from oval cells can be activated after
retrorsine administration and contribute to the regeneration in this
setting.. Similarly, the labeled precursors are a likely source of
labeled biliary cells that we observed after 2-AAF treatment.
However, another possibility is that labeled oval cells may also
differentiate in vivo into biliary epithelial cells. This would explain
why no labeled biliary cells were detected in the retrorsine model.
The bipotential capacity of oval cells has been already suggested
[1]. Oval cells are supposed to proliferate and form ductular
structures that communicate with the biliray system [30]. To our
knowledge, no direct in vivo lineage analysis has yet reported the
generation of biliary cells from oval cells in the liver and our data
are the first indication that such lineage analysis is feasible.
In conclusion our results demonstrate the validity of genetic
labeling to study cell fate in pathological conditions and support
the use of this strategy in future studies of hepatic regeneration.
Materials and Methods
Animals
Male Fischer 344 rats were used in this study. They were housed
at the Nantes School of Medicine animal facility. All surgical
procedures were conducted according to the guidelines of the
French Ministe `re de l9Agriculture. Rats were anesthetized by
isofluorane inhalation (3% v/v).
Two-thirds hepatectomy was performed according to [31].
Cyproterone acetate (CPA) was administered by force feeding
two consecutive days at a daily dose of 200 mg/kg. Triiodothy-
ronine (T3) was administered intra-peritoneally the second day
(day 2) at a dose of 4 mg/kg. Two injections of retrovirus (i.e
3610
9 infectious units/kg) were performed in the dorsal penile
vein [17]. In newborn animals, viral vectors were injected via the
temporal vein as described previously (1610
8 infectious units/rats)
[32].
Retrorsine was added to distilled water at 10 mg/ml and
titrated to pH 2.5 with 1N HCL to achieve dissolution.
Subsequently, the solution was neutralized using 1 N NaOH,
Lineage Analysis in Rat Liver
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and 0.15 mol/L NaCL (pH 7). Retrorsine was adminstered by
intra peritoneal injection. 2-AAF was incorporated at 0.02% in the
pellet chow.
Viral vector
We used amphotropic MoMULV recombinant retroviral
vectors containing the E.coli nlsLcZ gene encoding b-galactosidase
gene coupled to the nuclear localization signal from the SV40
large T antigene. The viral supernatant was prepared as previously
described [20] and the titer was routinely 10
9 infectious units/ml.
CTLA4-Ig recombinant adenoviral vectors were prepared by
the Vector Core of Nantes Hospital as previously described [19].
They harbor the sequence encoding the extracellular portion of
the murine CTLA4 fused to human IgG1 Fc fragment, placed
under the transcriptional control of the CMV promoter.
Recombinant CTLA4Ig adenoviral vectors were injected in the
tibialis anterior at a dose of 10
10 infectious particles/animal
immediately after injection of retroviral vectors.
Histology
The following antibodies were used on formalin-fixed/paraffin-
embedded sections (5 mm): Cytokeratines (rabbit anti-cow cyto-
keratine polyclonal ref Z062201 Dako, France 1:750), b-
galactosidase (1:1000), gamma glutamyl transpeptidase (GGT, gift
from Pr Laperche 1:150), b-catenin, (1/50), Mib5 antibody (anti
Ki67 antibody, 1:50). Citrate buffer antigen retrieval was used for
cytokeratines Mib5 and b-catenin. Primary antibodies were
incubated overnight at 4uC revealed with biotinylated goat anti-
mouse immunoglobulin and streptavidin-peroxidase using DAB as
a chromogenic substrate. Positive cells were counted on at least 10
fields at 406magnification, corresponding approximately to 3000
hepatocytes. For colocalization of cytokeratin and b-galactosidase,
anti CKs antibodies were incubated overnight at 4uC. After
washing, sections were incubated with Cy3-conjugated anti–rabbit
Ig (1/500) for 30 minutes. Anti b-galactosidase antibodies were
then applied for 2 hours and revealed with FITC-conjugated anti-
rabbit Ig for 30 minutes. Slides were visualized using Leica SP1
and image processing used Metamorph and ImageJ software.
b-galactosidase Assay
Beta-galactosidase activity was detected by fluorescence assy
using methyllumbelliferyl-b-D-galactoside as previously described
[12]. Fluorescence was measured on a fluorometer, with excitation
and emission wavelengths of 365 nm and 460 nm respectively.
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